Patient case (clinical description): A 63-year-old man comes to the clinic for recent unintentional weight loss. The patient also has epigastric discomfort after meals. He has no known medical problems and takes no medications. His blood pressure is 130/75 and pulse rate is 88/min. He is not febrile. Upper endoscopy shows a lesion in the stomach that shows typical features of diffuse-type adenocarcinoma presenting with signet ring cells that do not form glands.

Patient's own account: I went to the clinic because I had been losing so much weight that it was concerning. I'm a 63-year-old guy, and it is something rather unusual. I'm always suffering from stomachache after every meal. I've never been sick, and I don't take any medicine. The doctor took my blood pressure and told me it was 130/75, and my pulse rate was 88/min. I'm not febrile! I also had to do an endoscopy, and they found a lesion in my stomach that shows typical features of stomach cancer. I'm totally devastated...

Clinical trial: Neoadjuvant Chemotherapy Plus Chemoradiation in Patients With Potentially Resectable Gastric Carcinoma

Eligibility criteria:
Inclusion Criteria:

        1.18 ≤ age ≤ 70, Male or Female; 2.Minimum life expectancy of 6 months; 3.Patients with
        localized, histologically confirmed gastric or gastroesophageal adenocarcinoma; 4.Patients
        must have a performance status of < 2 Eastern Cooperative Oncology Group (ECOG); 5.No prior
        major surgery of the stomach or radiation therapy to the stomach or immunotherapy or
        chemotherapy; 6.CT or MRI, endorectal ultrasonography (EUS), laparoscopic exploration are
        required to stage; 7.Without other benign diseases such as lung, kidney, liver infections;
        8.Without participating other clinical trials; 9.Patient must sign an informed consent
        prior to study entry; 10.Patients must have adequate bone marrow function (defined as
        peripheral absolute granulocyte count of >1,500/µL, and platelet count of > 100,000/µL),
        adequate liver function (bilirubin <= 1.5 mg/dl), and adequate renal function (creatinine
        <= 1.5 mg/dl). 11)Patients without cardiac disease , severe uncontrolled diabetes,
        hypertension, cerebrovascular disease, or infection.

        Exclusion Criteria:

          1. Pregnant women are excluded from study entry due to the potential teratogenic effects
             of the study treatment;

          2. Female patients who planed to have a baby;

          3. Prior radiation therapy to the stomach, liver or kidney;

          4. Dysfunction of important organs such as liver, kidney or heart; 5.Abnormalities of
             mental status;

        6.Active coronary artery disease; 7.Cardiac arrhythmia, and need to receive medication
        therapy; 8.Severe uncontrolled hypertension; 9.Active clinical serious infection; 10.The
        known human immunodeficiency virus (HIV) infection history; 11.The known central nervous
        system diseases, including brain metastatic tumors; 12.Patients have had clinical clear
        gastrointestinal bleeding in 6 months; 13.Drug abuse; 14.Swallowing difficulties for drugs;
        15.Poor compliance; 16.Presence of concurrent or previous malignancies (except for cervical
        carcinoma in situ or basal cell carcinoma of the skin); 17.Presence of peritoneal
        metastasis, distant organs or lymph nodes metastasis; 18.Presence history of major surgery
        in the past three months; 19.Poor tolerability; 20.Prior history of medication; 21.allergy
        for chemotherapeutic drugs.
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.
Subject must be at most 70 Years

Eligibility (NLI label): Entailment